Compare SPB & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPB | NTLA |
|---|---|---|
| Founded | 1906 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.6B |
| IPO Year | 1994 | 2016 |
| Metric | SPB | NTLA |
|---|---|---|
| Price | $79.92 | $11.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 20 |
| Target Price | ★ $98.75 | $23.11 |
| AVG Volume (30 Days) | 291.2K | ★ 5.0M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $3,802,100,000.00 | $67,671,000.00 |
| Revenue This Year | $1.92 | N/A |
| Revenue Next Year | $1.26 | $143.36 |
| P/E Ratio | $80.07 | ★ N/A |
| Revenue Growth | ★ 20.86 | 16.92 |
| 52 Week Low | $51.41 | $7.95 |
| 52 Week High | $99.06 | $18.48 |
| Indicator | SPB | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 48.60 | 40.32 |
| Support Level | $77.74 | $10.15 |
| Resistance Level | $80.83 | $13.50 |
| Average True Range (ATR) | 1.77 | 0.76 |
| MACD | 0.61 | -0.09 |
| Stochastic Oscillator | 81.51 | 20.26 |
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.